Core Viewpoint - Marubi Biotechnology (丸美生物) is planning to issue H-shares to raise funds aimed at enhancing its core strategies, including strengthening its omni-channel sales system, improving brand value, incubating new brands, enhancing R&D capabilities, optimizing the supply chain, and supplementing working capital, with the goal of improving overall competitiveness [1][2] Group 1: Company Strategy and Market Position - The company has been focused on the anti-aging skincare industry for over 20 years, leveraging synthetic biology technology and core breakthroughs in research and development, particularly in recombinant collagen products [1] - According to a Frost & Sullivan report, Marubi is the third largest beauty company in China in the recombinant collagen skincare segment, based on retail sales projected for 2024 [1] - Marubi has established an integrated R&D platform that encompasses synthetic biology, protein engineering, green chemistry, natural plant extraction, and bio-fermentation, continuously launching new ingredients and products to support business growth [1] Group 2: Fundraising and Use of Proceeds - The company has developed over 80 proprietary ingredients, including recombinant double collagen and super molecular cotton flower extract, with more than 30 achieving large-scale production as of September 30, 2025 [2] - The funds raised from the H-share issuance will be used to build a comprehensive omni-channel sales system, enhance brand value through diversified marketing activities, expand the R&D team, upgrade R&D facilities, improve supply chain capabilities, and support working capital [2] - The issuance will not change the company's control, with Dr. Sun Huaqing and Wang Xiaopu remaining the actual controllers [2] Group 3: Competitive Advantage and Future Outlook - Marubi's brand has ranked first in China's domestic eye care market for four consecutive years, while its "Lianhuo" brand ranks third among domestic foundation brands [3] - The anti-aging skincare segment is the fastest-growing sub-sector in China's skincare industry, and the company aims to leverage this growth opportunity through continued investment in core technology R&D [3] - As of September 30, 2025, the company has applied for 651 patents globally, with 265 authorized invention patents, positioning its R&D strength among the top in domestic beauty enterprises [3] - The H-share issuance is viewed as a strategic decision for long-term development, enhancing capital strength and core competitiveness, and laying a solid foundation for sustainable growth and shareholder value creation [3]

Core Insights - The article highlights the significant innovation achieved by the Chinese biotechnology company, Juzhibio, in the field of recombinant collagen, particularly recombinant type IV collagen, overcoming technical bottlenecks through synthetic biology advantages [1][2][3]. Group 1: Technological Breakthroughs - Juzhibio has made substantial progress in the production of recombinant type IV collagen, achieving high activity and purity in large-scale production through advancements in expression systems, production processes, and efficacy validation [1][2]. - The company utilized Pichia pastoris as an expression host, achieving a secretion yield of approximately 25.1 g/L with a purity of over 90%, addressing the economic feasibility of large-scale production [3]. - Juzhibio conducted the first systematic scientific validation in China regarding the mechanism of recombinant type IV collagen's effect on skin basement membrane integrity, confirming its ability to promote the synthesis and expression of key substances in the basement membrane [4]. Group 2: Market Applications - The core technology in recombinant type IV collagen has been effectively applied to Juzhibio's consumer brand "Kefumei," resulting in successful market products such as the "Kefumei Collagen Stick 2.0," which addresses modern consumer skincare needs [6]. - Juzhibio has also developed a specialized product line, "Kefumei Frame Domain Repair Series," targeting post-aesthetic care, thus tapping into a high-growth market segment [7]. Group 3: Industry Leadership - Juzhibio has established a robust patent portfolio with 186 patents and applications, positioning itself as a leader in the global intellectual property landscape within the biotechnology sector [9]. - The company actively participates in the formulation of industry standards, having contributed to multiple standards related to recombinant collagen, thereby promoting scientific and transparent development in the industry [9]. - Juzhibio has expanded its global market presence, successfully entering markets in Canada, the USA, Japan, South Korea, Singapore, and Thailand, showcasing the capability of Chinese enterprises in the forefront of life sciences [10].

Core Insights - The shift in consumer behavior towards ingredient-focused purchasing in the beauty industry is becoming mainstream, particularly among Generation Z, with over 90% of respondents in a survey indicating that researching materials and ingredients is a wiser choice when buying products [1] - Marubi Biotechnology has submitted its listing application to the Hong Kong Stock Exchange, aiming to become a dual-listed company (A+H), which will enhance its international financing channels and global brand influence [1] Group 1: Company Strategy and Innovation - Marubi Biotechnology focuses on biotechnological advancements in the beauty sector, particularly in anti-aging and skin repair products, establishing an integrated R&D platform from basic research to production [1] - The company has invested over 250 million yuan in R&D since 2022, collaborating with around 30 top global universities and research institutions, and holds 375 authorized patents, leading the Chinese beauty industry in the number of invention patents [2] - Marubi has made significant breakthroughs in recombinant collagen, developing a recombinant double collagen that enhances biological similarity, activity, stability, and scalability in production [2] Group 2: Financial Performance and Market Position - From 2022 to 2024, Marubi's revenue grew from 1.732 billion yuan to 2.97 billion yuan, with a compound annual growth rate (CAGR) of 31%, while net profit increased from 167 million yuan to 342 million yuan, with a CAGR of 43% [4] - The company's online direct sales revenue share surged from 46.4% in 2022 to 74.8% in the first three quarters of 2025, leveraging major e-commerce platforms like Douyin, Tmall, and Kuaishou [4] - Marubi is recognized as the third-largest beauty company in China within the recombinant collagen skincare segment, establishing a strong competitive moat [4]

Core Viewpoint - The collagen market is undergoing significant changes with the approval of new products from Chongshan Bio and Aibai Rui, expanding the competitive landscape in the animal-derived collagen sector. The focus is shifting towards differentiation in terms of cost-effectiveness, brand recognition, product safety, and efficacy as the market becomes increasingly crowded [1][2]. Group 1: New Product Approvals - Chongshan Bio's new product is the world's first collagen implant with a concentration of 45mg/ml, aiming to establish a strong product image through high concentration [2]. - Aibai Rui's new product targets specific needs by improving cheek smoothness, attempting to create a niche in the market despite similarities to existing products [4]. Group 2: Market Dynamics - The animal-derived collagen market has formed an "eight strong" competitive landscape, with established players like Shuangmei Bio leading the market due to their early entry and established brand recognition [6]. - New entrants are focusing on differentiation strategies, such as high-quality ingredients and innovative product forms, to compete effectively [6]. Group 3: Growth of Recombinant Collagen - The recombinant collagen market is experiencing rapid growth, with a projected compound annual growth rate (CAGR) of 41.4% from 2023 to 2027, surpassing the 27.7% CAGR of animal-derived collagen [8]. - The market size for recombinant collagen products in 2023 is estimated at 28.63 billion yuan, slightly below the 29.79 billion yuan for animal-derived collagen, indicating a shift in consumer preference towards recombinant options [8]. Group 4: Competitive Landscape and Future Outlook - The approval of new recombinant collagen products is intensifying competition, with companies like Jinjian Bio and others entering the market, challenging the previous dominance of Jinbo Bio [9]. - The future of the collagen market will likely see increased competition, with a focus on cost-effectiveness, brand strength, and product efficacy becoming critical for success [12].

Core Viewpoint - Marubi Biotechnology (丸美生物) is planning to issue H-shares to raise funds aimed at enhancing its core strategies, including strengthening its omni-channel sales system, improving brand value, incubating new brands, enhancing R&D capabilities, optimizing the supply chain, and supplementing working capital, with the goal of improving overall competitiveness [1][2] Group 1: Company Strategy and Financial Plans - The funds raised from the H-share issuance will be used entirely to reinforce the company's core strategies, including building a comprehensive omni-channel sales system and enhancing brand value through diversified marketing activities [1][2] - The company emphasizes that the H-share issuance will not lead to a change in control, with Dr. Sun Huaqing and Wang Xiaopu remaining the actual controllers [2] - Marubi plans to invest in both online and offline direct-to-consumer (DTC) capabilities, expand its R&D team, upgrade R&D facilities, and improve supply chain capabilities [2] Group 2: Market Position and Competitive Advantage - Marubi has established a closed-loop value chain for core raw materials, having developed over 80 proprietary ingredients, with more than 30 achieving large-scale production [2] - The company holds 651 global patent applications and has been granted 265 invention patents, positioning its R&D strength among the top in the domestic beauty industry [3] - Marubi's brand has ranked first in China's eye care market for four consecutive years, while its "Lianhuo" brand ranks third in the domestic foundation market [3] Group 3: Industry Growth and Future Outlook - The anti-aging skincare segment is the fastest-growing sub-sector in China's skincare industry, presenting significant growth opportunities for Marubi [3] - The H-share issuance is viewed as a strategic decision for long-term development, aligning with industry trends and enhancing the company's capital strength and core competitiveness [3]

Core Viewpoint - Guangdong Marubi Biotechnology Co., Ltd. plans to raise funds through H-share issuance to strengthen its core strategies, enhance its comprehensive competitiveness, and improve its operational capabilities [1][3] Group 1: Company Overview - Marubi has been focused on the anti-aging skincare industry for over 20 years, leveraging synthetic biology technology and core breakthroughs in recombinant collagen [2] - According to a Frost & Sullivan report, Marubi is the third largest beauty company in China in the recombinant collagen skincare segment based on retail sales in 2024 [2] Group 2: Fundraising Purpose - The funds raised will be used to enhance the company's multi-channel sales system, improve brand value, incubate new brands, strengthen R&D capabilities, optimize the supply chain, and supplement working capital [1][3] - Specific plans include building direct-to-consumer (DTC) capabilities, diversifying marketing activities, expanding the R&D team, and upgrading R&D facilities [3] Group 3: Brand Positioning - Marubi's brand has ranked first in China's eye care market for four consecutive years, while its "Lianhuo" brand ranks third among domestic makeup brands [3] - The company has developed over 80 proprietary ingredients, with more than 30 achieving large-scale production, establishing a closed-loop value chain from basic research to application [2] Group 4: Shareholder Return Strategy - Marubi emphasizes a shareholder return plan, prioritizing cash dividends, with a commitment to distribute at least 10% of the annual distributable profits in cash [4] - The company aims to leverage growth opportunities in the anti-aging skincare market, which is the fastest-growing segment in China's skincare industry [4] Group 5: Long-term Development Strategy - The H-share issuance is a strategic decision for long-term development, aligning with industry trends to enhance capital strength and core competitiveness [5] - Effective use of the raised funds will support product innovation and market expansion, laying a solid foundation for sustainable long-term growth [5]

Core Viewpoint - The Chinese beauty brand Marubi Biotechnology (丸美生物) is preparing for a Hong Kong IPO after experiencing a modest stock performance in A-shares, with a year-to-date increase of only 5.3% compared to significant gains by its Hong Kong counterparts [2][3]. Group 1: Company Overview - Marubi Biotechnology was founded in April 2002 and went public on the Shanghai Stock Exchange in July 2019 [3]. - The company focuses on synthetic biology technology and has developed skincare products with anti-wrinkle, firming, and repairing effects, particularly through its core technology of recombinant collagen [3]. - Marubi operates two main brands: Marubi, which specializes in eye and facial care solutions, and Lianhuo, a cost-effective makeup brand focusing on base makeup products [3]. Group 2: Financial Performance - Marubi's revenue from 2022 to 2024 was reported as 1.732 billion RMB, 2.226 billion RMB, and 2.970 billion RMB, with a compound annual growth rate (CAGR) of 31.0% [6]. - The net profit for the same period was 167 million RMB, 278 million RMB, and 342 million RMB, achieving a CAGR of 43.0% [6]. - However, net profit growth has slowed significantly, with a year-on-year increase of only 2.9% in the first nine months of the current year [6]. Group 3: Sales Channels - Marubi's sales channels include both online and offline, with online direct sales through platforms like Douyin, Tmall, and JD.com, and offline sales through distributors to specialty stores, department store counters, and beauty salons [5]. - The proportion of revenue from online direct sales has increased from 46.4% in 2022 to 74.8% in the first nine months of 2025, indicating a strong shift towards online sales [7]. Group 4: Dividend Policy and Controversy - Marubi has faced controversy over its substantial dividend payouts, which totaled 76.2 million RMB, 100 million RMB, 309 million RMB, and 301 million RMB from 2022 to 2025 [12]. - The company's significant dividends have raised questions among investors, especially in light of declining net profit growth and the potential impact on cash reserves [11][12]. - The major shareholders, Sun Huaqing and Wang Xiaopu, hold approximately 80.8% of the company, leading to concerns about the alignment of interests between the company and its investors [12]. Group 5: Future Plans - Marubi plans to use the funds raised from its IPO for enhancing its online and offline consumer engagement capabilities, marketing activities, and expanding its R&D team [13]. - The company aims to improve its supply chain capabilities and general working capital through the proceeds from the IPO [13].

Core Viewpoint - Huaxi Biological, a leading player in the medical beauty industry, is currently facing significant challenges as the hyaluronic acid market experiences diminishing returns, leading to a decline in revenue and profit [3][5]. Group 1: Financial Performance - In the first three quarters of this year, Huaxi Biological's revenue decreased by 18.36% to 3.163 billion yuan, while net profit attributable to shareholders fell by 30.29% to 252 million yuan [5]. - As of December 5, Huaxi Biological's stock closed at 45.57 yuan, below its IPO price of 47.79 yuan, with a market capitalization of only 22 billion yuan, a drop from its peak of 140 billion yuan [5]. - By the third quarter of 2025, the company's revenue was 903 million yuan, down 15.16%, while net profit attributable to shareholders increased by 55.63% to 32 million yuan [14]. Group 2: Product and Brand Strategy - Huaxi Biological's skincare products, primarily based on hyaluronic acid, have seen a significant revenue decline, with a 33.97% drop in the first half of 2025, contributing to 40.36% of the company's main business revenue [9]. - The company has decided to eliminate several underperforming sub-brands, including Runxihe, Runxiquan, and Demarun, in an effort to focus on its core brands [9][11]. - The revenue from core brands like Kuadi and Runbaiyan has also shown signs of fatigue, with both brands expected to fall below the 1 billion yuan revenue mark by 2024 [10][17]. Group 3: Market Dynamics - The cosmetic market is experiencing intense competition, with a significant increase in the number of hyaluronic acid products, leading to market saturation and reduced consumer interest [16]. - The price war in the hyaluronic acid sector has intensified, with products like Joia's hyaluronic acid being sold at drastically reduced prices, marking the end of high-profit margins in the industry [17]. - The overall market for functional skincare products is projected to reach 211.8 billion yuan by 2025, with collagen expected to surpass hyaluronic acid as the leading ingredient [21]. Group 4: Future Outlook - Huaxi Biological is undergoing a transformation, shifting its focus from skincare to new areas such as weight loss and small nucleic acid drugs, investing 138 million yuan in a strategic partnership with Saint Pharma [24]. - The company is rebranding its skincare product line to emphasize technological innovation, indicating a shift in strategy to adapt to changing market conditions [24].

Core Viewpoint - Marubi Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with Goldman Sachs and CITIC Securities as joint sponsors. The company ranks third in the Chinese market for recombinant collagen skincare products by retail sales in 2024, focusing on anti-aging skincare through synthetic biology technology [1][2]. Group 1: Company Overview - Marubi operates two main brands: Marubi (丸美) and L'HOTEL (恋火). The Marubi brand specializes in eye and facial anti-aging care, holding the top position in retail sales for eye care brands in China from 2021 to 2024. L'HOTEL focuses on base makeup products, ranking third among domestic base makeup brands and fifth overall in China for retail sales in 2024 [2]. - The company has developed over 80 proprietary ingredients, including recombinant double collagen and SPGβ-glucan, with more than 30 products achieving large-scale production. It operates two production bases in Guangzhou, equipped with high-density fermentation and purification processes for recombinant collagen production [2]. Group 2: Industry Position and Innovations - According to a report by Frost & Sullivan, Marubi ranks third in the recombinant collagen skincare segment in China by retail sales for 2024. The company has successfully developed recombinant double collagen, an engineered product that combines type I and type III collagen using translation pause and C-PRO loop technology [1]. - As of September 30, 2025, Marubi is the first and only company in China approved as a national research center for recombinant functional protein technology, having been recognized as a key drafting unit for the industry standard "Recombinant Soluble Collagen" by the Ministry of Industry and Information Technology [1].

Company Overview - Guangdong Marubi Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Goldman Sachs and CITIC Securities as joint sponsors [1] - Marubi is the third largest beauty company in China's recombinant collagen skincare segment based on retail sales projected for 2024 [1] - The company focuses on providing anti-aging solutions and has over 20 years of experience in the skincare industry, leveraging synthetic biology technology [1] Product Development - Marubi has successfully developed recombinant double collagen, which combines type I (profile) collagen and type III (filling) collagen into a single molecule [1] - The company has established a comprehensive value chain covering basic research to application, having developed over 80 proprietary ingredients, with more than 30 achieving large-scale production [3] Brand Performance - Marubi and its brand "Lianhuo" are the main brands, with Marubi ranking first in China's eye care brand market from 2021 to 2024 based on retail sales [2] - Lianhuo ranks third among domestic foundation brands and fifth among all foundation brands in China, with a compound annual growth rate (CAGR) of 77.5% from 2022 to 2024 [2] Financial Performance - The company recorded revenues of RMB 1.732 billion, RMB 2.226 billion, RMB 2.970 billion, and RMB 2.450 billion for the years 2022, 2023, 2024, and the nine months ending September 30, 2025, respectively [4] - The annual profits for the same periods were RMB 167 million, RMB 278 million, RMB 342 million, and RMB 247 million [5] - Gross profits for the respective years were RMB 1.175 billion, RMB 1.560 billion, RMB 2.177 billion, and RMB 1.834 billion [6] Industry Overview - The Chinese beauty industry is projected to grow from RMB 460.3 billion in 2019 to RMB 566.3 billion in 2024, with a CAGR of 4.2% [7] - The skincare market is expected to grow from RMB 355.9 billion in 2019 to RMB 451.4 billion in 2024, with a CAGR of 4.9% [8] - The makeup market is anticipated to grow from RMB 104.5 billion in 2019 to RMB 114.8 billion in 2024, with a CAGR of 1.9% [9]